REACX
Live / Applied — Fourth extension granted (statement of use) (as of 25 Feb 2026)
What this means for you
Not registered yet, but its 28 Nov 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97694234
- Mark type
- Stylized text
- Filed
- 28 Nov 2022
- Published for opposition
- 02 Jan 2024
- Attorney of record
- Katharyn Bond
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of addiction to and abuse of alcohol, opiates, narcotics and other addictive or habit forming substances, for central nervous disorders, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular disease, circulatory system disease, intestinal disorders, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease; implantable delivery systems comprised of a subcutaneous drug delivery device sold filled with sustainable release pharmaceutical preparations used in the treatment of addiction to and abuse of alcohol, opiates, narcotics and other addictive or habit forming substances, central nervous disorders and other serious and life-threatening diseases, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular disease, circulatory system disease, intestinal disorders, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease; pharmaceuticals, namely, implantable drug delivery system comprised of a subcutaneous drug delivery device sold filled with a polymer-based subdermal matrix formulation for the sustained release of drugs in the treatment of opiate addiction; pharmaceuticals, namely, implantable drug delivery system comprised of a subcutaneous drug delivery device sold filled with a polymer-based matrix formulation for the sustained release of drugs in the treatment of central nervous system disorders and other serious and life-threatening diseases
Owner
- Dominic Leslie, Pasadena, CA, US
- Dominic Leslie, Pasadena, CA, US
Prosecution history
- 26 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Feb 2026 — SOU EXTENSION 4 GRANTED
- 25 Feb 2026 — SOU EXTENSION 4 FILED
- 25 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 26 Aug 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Aug 2025 — SOU EXTENSION 3 GRANTED
- 25 Aug 2025 — SOU EXTENSION 3 FILED
- 25 Aug 2025 — SOU TEAS EXTENSION RECEIVED
- 25 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Feb 2025 — SOU EXTENSION 2 GRANTED
- 24 Feb 2025 — SOU EXTENSION 2 FILED
- 24 Feb 2025 — SOU TEAS EXTENSION RECEIVED
- 06 Aug 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 06 Aug 2024 — SOU EXTENSION 1 GRANTED
- 06 Aug 2024 — SOU EXTENSION 1 FILED